Valion Bio, Inc. (VBIO) stock
VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.50−0.04 (-7.55%)
Close on Nov 18, 2026Market cap $2.09MP/E –Yield –
Valion Bio gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Valion Bio's gross profit for the twelve months ending Sep 30, 2025 was -$280.00K, down 213.8% year over year. For fiscal 2024 it was $2.00K, down 99.3% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.00K | -99.3% |
| FY2023 | Dec 31, 2023 | $287.00K | -4.0% |
| FY2022 | Dec 31, 2022 | $299.00K | – |
| FY2021 | Dec 31, 2021 | -$38.00K | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | -$145.00K | -429.5% |
| Q2 FY2025 | Jun 30, 2025 | $54.00K | +80.0% |
| Q1 FY2025 | Mar 31, 2025 | $50.00K | -70.1% |
| Q4 FY2024 | Dec 31, 2024 | -$239.00K | -4880.0% |
| Q3 FY2024 | Sep 30, 2024 | $44.00K | -59.3% |
| Q2 FY2024 | Jun 30, 2024 | $30.00K | -50.8% |
| Q1 FY2024 | Mar 31, 2024 | $167.00K | +47.8% |
| Q4 FY2023 | Dec 31, 2023 | $5.00K | -88.4% |
| Q3 FY2023 | Sep 30, 2023 | $108.00K | +71.4% |
| Q2 FY2023 | Jun 30, 2023 | $61.00K | -51.2% |
| Q1 FY2023 | Mar 31, 2023 | $113.00K | +61.4% |
| Q4 FY2022 | Dec 31, 2022 | $43.00K | – |
| Q3 FY2022 | Sep 30, 2022 | $63.00K | – |
| Q2 FY2022 | Jun 30, 2022 | $125.00K | – |
| Q1 FY2022 | Mar 31, 2022 | $70.00K | +218.2% |
| Q4 FY2021 | Dec 31, 2021 | -$2.00K | – |
| Q3 FY2021 | Sep 30, 2021 | -$26.00K | – |
| Q2 FY2021 | Jun 30, 2021 | -$33.00K | – |
| Q1 FY2021 | Mar 31, 2021 | $22.00K | – |
See a number that looks wrong?